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Summary
 
Myocardial infarction in humans provokes an acute phase response, and C-reactive protein
(CRP), the classical acute phase plasma protein, is deposited together with complement within
the infarct. The peak plasma CRP value is strongly associated with postinfarct morbidity and
mortality. Human CRP binds to damaged cells and activates complement, but rat CRP does not
activate complement. Here we show that injection of human CRP into rats after ligation of the
 
coronary artery reproducibly enhanced infarct size by 
 
z
 
40%. In vivo complement depletion,
produced by cobra venom factor, completely abrogated this effect. Complement depletion also
markedly reduced infarct size, even when initiated up to 2 h after coronary ligation. These ob-
servations demonstrate that human CRP and complement activation are major mediators of isch-
emic myocardial injury and identify them as therapeutic targets in coronary heart disease.
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I
 
schemia caused by coronary artery occlusion is the pri-
mary process underlying acute myocardial infarction, but
inflammation around the zone of hypoxic necrosis also
makes a major contribution to the final size of the lesion and
the clinical outcome (1). Local activation of complement,
which starts within 2 h of acute ischemic injury (2), and in-
filtration of neutrophils are universal features of both clini-
cal and experimentally induced acute myocardial infarction
(1). In experimental animals, inhibition of complement ac-
tivation at the time of coronary artery occlusion both pre-
vents neutrophil infiltration (3) and markedly reduces infarct
size (4–8). The mechanisms that initiate complement activa-
tion are not known (9), although loss of CD59 (protectin)
from cells compromised by anoxia may contribute to direct
damage by the terminal complement complex (2).
The circulating concentration of human C-reactive pro-
tein (CRP),
 
1
 
 the classical acute phase protein, is always in-
creased after acute myocardial infarction, starting within
4–6 h of the onset of symptoms and reaching a peak after
 
z
 
50 h (10, 11). This peak value is associated with out-
come, both early and late. Ventricular rupture occurs only
in patients with peak serum CRP levels 
 
.
 
200 mg/liter (12),
and high CRP levels predict mortality over the next 6 mo
from all causes related to myocardial infarction (13). Fur-
thermore, at autopsy, as originally demonstrated in rabbits
by Kushner et al. (14), CRP is found deposited on myocar-
dial cells within the infarcted area, together with activated
complement (15).
Human CRP, after aggregation or ligand binding, is a po-
tent activator of the classical complement pathway (16–20),
and, based on both experimental and clinical observations,
we have previously discussed the possible proinflammatory
role of CRP in exacerbating tissue injury during the acute
phase response (21, 22). Hack et al. (23) and Beranek (24, 25)
have lately returned to this concept, highlighting the po-
tential pathogenetic importance of CRP binding to nonir-
remediably damaged cells leading to complement activa-
tion. This would opsonize the targeted cells and/or cause
direct cytotoxicity, thereby increasing the amount of cell
death as well as adding to the proinflammatory activity of
complement activated by CRP or other mechanisms in the
zone of direct ischemic necrosis (1, 2, 9).
We have now investigated this mechanism directly and
show here, for the first time, that parenteral injection of
human CRP does indeed markedly enhance tissue damage,
via a complement-dependent mechanism, in experimental
acute myocardial infarction produced by coronary artery li-
gation. In addition, we demonstrate that even initiation of
complement depletion 2 h after coronary artery ligation
still dramatically reduces infarct size. These findings have
potentially major therapeutic implications.
 
1
 
Abbreviations used in this paper:
 
 CRP, C-reactive protein; NBT, nitroblue
tetrazolium; SAP, serum amyloid
 
 
 
P
 
 
 
component. 
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Materials and Methods
 
Protein Reagents and Assays.
 
Human CRP (26), human serum
amyloid
 
 
 
P
 
 
 
component (SAP; reference 27), rat CRP (28), rat C3
(28), and cobra (
 
Naja naja
 
) venom factor (29) were isolated and
purified and/or assayed precisely as previously described. The
preparations of human CRP and SAP and of cobra venom factor
used in vivo were all 
 
.
 
99% pure.
 
Induction and Measurement of Myocardial Infarction. 
 
Female Wistar
rats bred at Imperial College School of Medicine, Hammersmith
campus were used at age 9–10 wk and weighed 230–280 g.
Within each experiment, the whole body and heart weights were
the same in control and experimental groups. All animals were
carefully examined and were healthy before fasting overnight be-
fore surgery. General anesthesia was induced with inhaled isoflu-
rane, and supplemental oxygen was provided at 1.0 liter/min.
The chest was opened through the sixth intercostal space, anes-
thesia was discontinued but supplemental oxygen continued at
0.5 liter/min, and the pericardium was opened to allow the heart
to be lifted out of the thorax. The left anterior descending coro-
nary artery was immediately ligated at a constant distance just be-
low the atrium with a 5/0 silk suture, the heart was replaced, and
the chest was closed while active ventilation with 100% oxygen
was continued. The duration of pneumothorax was 
 
z
 
30 s. Re-
suscitation was completed by gentle chest massage with the rat ly-
ing supine, and there was usually rapid recovery of consciousness
and the righting reflex. Buprenorphine (0.05 mg/kg) was given
immediately for postoperative analgesia and repeated 12-hourly.
Development of myocardial infarction was confirmed by early
postoperative four lead electrocardiogram showing marked ST seg-
ment elevation in leads I and aVL as well as various arrhythmias.
Intraoperative and immediate postoperative mortality was up
to 20%, but thereafter there were few deaths before day 5, when
the rats were killed for measurement of infarct size. Deep anes-
thesia was induced with isoflurane, and the hearts were excised
while still beating in sinus rhythm and immediately arrested in di-
astole by immersion in 10 ml of 30 mM KCl. They were then
cleaned of any extraneous adherent tissue and weighed before be-
ing briefly chilled at 
 
2
 
20
 
8
 
C to produce sufficient rigidity to facil-
itate cutting into defined sections. Each heart was cut into four
slices of equal thickness perpendicular to the course of the left
coronary artery, starting from the apex of the heart and ending at
the position of the ligature around that artery. These slices were
designated A, B, C, and D starting from the apex, and each was
washed with pure water and then immersed in 0.02 M phosphate
buffer, pH 7.4, containing 0.5 mg/ml of nitroblue tetrazolium
(NBT; Sigma Chemical Co.) at 37
 
8
 
C for 30 min. NBT stains vi-
able but not infarcted myocardium. After staining with NBT, the
slices were washed briefly in cold water before fixation in 10%
buffered formalin for 48 h, and the proximal cut surface of each
slice was then imaged under standard conditions with a high res-
olution digital camera. The captured images were coded and ana-
lyzed ‘blind,’ without knowledge by the operators of the treat-
ment received by the rat in question. Lines were drawn around
the total area of the slice, the NBT-negative infarct zone, and any
parts of the image to be excluded from the estimation, including
valves, chordae tendinae, shadows, and edges, and the area of the
infarct was determined as a percentage of the total area. The in-
farcts were confined to slices B, C, and D, and the mean percent-
age in these three was taken as the infarct size in each heart. Sta-
tistical significance of differences between infarct sizes in different
treatment groups within each experiment was sought by one-way
analysis of variance and by Bonferroni 
 
t
 
 tests.
 
In Vivo Treatments.
 
Complement depletion was induced in
vivo by a single intraperitoneal injection of cobra venom factor at
250 U/kg. Human CRP or SAP was injected intraperitoneally at
40 mg/kg 1 h after coronary artery ligation and then at 24-h in-
tervals until the rats were killed on day 5. The proteins were dis-
solved in 10 mM Tris and 140 mM NaCl, pH 8.0, and also 2 mM
CaCl
 
2
 
 in the case of human CRP, and the control rats received
injections of the buffer alone at the same intervals. In one experi-
ment, rats were killed 24, 48, and 72 h after coronary artery liga-
tion. For analysis of the effect of cobra venom factor on plasma
C3, the usual dose was given and normal, unoperated rats were
bled from the tail at intervals up to 6 d. For measurement of
plasma clearance of human CRP and SAP, normal unoperated
rats received a single 40 mg/kg dose of each protein and were
bled at intervals up to 72 h later. Plasma clearance of human
CRP was also studied in the same protocol in normal unoperated
rats that had received cobra venom factor 24 h previously. These
experiments could not be performed in rats that had undergone
coronary artery ligation because they do not survive the anesthe-
sia required for bleeding, but there is no reason to suppose that
the results in those rats would be significantly different.
 
Immunohistochemical Analysis.
 
The formalin-fixed heart slices
were embedded in wax and sectioned at 2-
 
m
 
m thickness for rou-
tine hematoxylin and eosin staining and for immunohistochemical
staining. Optimal dilutions of the IgG fractions of monospecific
goat anti–human CRP, rabbit anti–rat CRP, and sheep anti–rat
C3 antisera, raised by immunization with the respective isolated
pure antigens, were used as primary antibodies after blocking the
sections by incubation in 20% vol/vol normal serum of the spe-
cies of origin of the secondary antibody. In all cases, endogenous
peroxidase activity was blocked by incubation with H
 
2
 
O
 
2
 
 before
testing. Secondary antibodies were optimal dilutions of goat anti–
rabbit IgG or rabbit anti–goat IgG (both from DAKO Corp.),
which cross-reacts with sheep IgG. Finally, rabbit or goat peroxi-
dase–antiperoxidase complexes (DAKO Corp.) were used, followed
by visualization with diaminobenzidine. All positive staining was
completely abolished when the primary antibodies had been ab-
sorbed before use with an excess of the respective specific anti-
gen. In the case of rat C3, which was not available in pure form,
parallel absorptions of the sheep anti–rat C3 antibody were per-
formed with normal rat serum and with C3-depleted serum from
a cobra venom–treated rat. The latter did not affect anti-C3 stain-
ing, whereas C3-sufficient rat serum abolished it completely. To
confirm that the antigens under investigation were not affected
by formalin fixation and tissue processing, sample hearts were
snap frozen without fixation, and 5-
 
m
 
m cryostat sections were
cut for immunoperoxidase staining. For all antigens, appearances
were identical to those of the fixed sections, except for poorer
preservation of histological detail as expected. Frozen sections of
a heart from a human CRP–treated rat killed on day 3 were also
stained for human CRP by indirect immunofluorescence and the
nuclei counterstained with ethidium bromide to visualize binding
of CRP to cell surfaces.
 
Results
 
Infarct Size Is Increased by Human CRP.
 
We have previ-
ously shown that rat CRP does not activate rat comple-
ment, whereas human CRP does so very efficiently (28).
The rat model therefore permits specific analysis of the
complement-dependent effect of human CRP on infarct
size in vivo. Rats that received 40 mg/kg of isolated pure 
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human CRP by intraperitoneal injection 1 h after coronary
artery ligation rapidly became clinically less well than
buffer-treated controls, and some died during the next 3 d
while receiving further daily injections of the same dose of
human CRP. In contrast, rats that had not been operated
on but received the same doses of human CRP showed
absolutely no ill effects. Injections of human SAP, the pen-
traxin protein very closely related to CRP (30), had no ad-
verse clinical effects in either normal or coronary artery–
ligated rats. When all surviving animals were killed on day 5
after coronary artery ligation, the infarcts in those receiving
human CRP were 
 
z
 
40% larger than in control rats
treated with either buffer or human SAP (Table I).
The plasma clearance of human CRP and SAP after sin-
gle intraperitoneal injections in control, nonoperated rats
and the clearance of human CRP in decomplemented rats
is shown in Fig. 1. The clearance of human CRP was not
affected by complement depletion. The peak values for hu-
man CRP were comparable to massive acute phase responses
in humans (31), and those for human SAP were much higher
than ever seen in humans (32). Rats that have undergone
coronary artery ligation do not survive the anesthesia re-
quired for bleeding and were therefore not bled before
they were killed on day 5. However, when these animals
were killed 24 h after the last of five daily injections, the se-
rum concentrations of human CRP were still in the range
of 13–53 mg/liter, typical of a moderate clinical acute phase
response in humans. In animals that had received human
SAP, the serum concentrations of this protein were between
45 and 175 mg/liter. Values for rat CRP in serum at the time
of exsanguination 5 d after coronary artery ligation were
215–525 mg/liter, which is within the normal range for
this species (28).
 
Complement Dependence of the Enhancement of Infarct Size
by Human CRP. 
 
Administration of cobra venom factor
in vivo rapidly produces profound and sustained depletion
of C3 (29), with no active C3 remaining in the circulation
at 6 h. Traces of C3 antigen detectable thereafter are inactive
cleavage fragments (33). With the dose of cobra venom fac-
tor used here, 250 U/kg (29), active C3 starts to reappear
 
in the circulation after 
 
z
 
4 d and is within the normal range
by day 5 or 6. When rats had been decomplemented by in
vivo administration of cobra venom factor 24 h before coro-
nary artery ligation, their infarcts at 5 d were 
 
z
 
60% smaller
than those in control untreated animals (Table II). Comple-
ment-sufficient rats injected daily with human CRP devel-
oped, as before, infarcts 
 
z
 
40% larger than those in control
untreated animals. However, injection of human CRP had
no effect at all on the reduced infarct size in decomplemented
rats (Table II). The damaging effect of human CRP in this
model is thus absolutely complement dependent.
 
Deposition of CRP and Complement in Rat Myocardial
Infarcts.
 
Human CRP and rat C3 (Fig. 2) and rat CRP (not
shown) were all deposited in the infarcted myocardium. On
day 5, human and rat CRP were present homogeneously
throughout the infarcted muscle and also in a more intense,
speckled pattern in multiple foci that occasionally coin-
 
Table I.
 
Human CRP Increases Myocardial Infarct Size in Rats
 
Treatment No. treated Day 5 survivors
Infarct size
mean (SD)
Bonferroni 
 
t
 
 test
vs. controls
 
%
Experiment 1
 
Buffer only 5 5 14.5 (1.1) –
Human CRP 5 4 21.2 (2.0)
 
P
 
 
 
5
 
 0.0007
 
Experiment 2
 
Buffer only 3 3 12.8 (0.9) –
Human SAP 5 5 12.4 (1.9) NS
Human CRP 5 3 17.6 (0.4)
 
P
 
 
 
5
 
 0.0022
Human CRP or SAP was injected intraperitoneally at 40 mg/kg.
Figure 1. Plasma clearance of human CRP and SAP after single intra-
peritoneal injections of 40 mg/kg in normal adult female rats weighing
230–280 g. Each data set represents values in a single animal. h, human
CRP in untreated rats; m, human CRP in rats decomplemented by intra-
peritoneal injection of 250 U/kg of cobra venom factor 24 h beforehand;
d, human SAP in untreated rats. 
1736
 
Human C-reactive Protein Enhances Tissue Damage in Myocardial Infarction
 
cided with hematoxyphil nuclear remnants. These foci may
be nuclear ghosts from which chromatin has been cleared but
that retain the small nuclear ribonucleoprotein particles to
which human CRP binds avidly (34, 35) and possibly other
CRP ligands. Rat C3 was present predominantly in the same
speckled foci, with no diffuse immunoreactivity on the in-
farcted muscle cells, in contrast to the distribution of CRP.
Immunofluorescence staining of sections of unfixed, snap-
frozen myocardial tissue taken 72 h after coronary ligation
clearly demonstrated the presence of CRP on the surfaces
of damaged myocardial cells in and around the infarct, as well
as the same distribution seen in fixed sections stained by the
immunoperoxidase method. Staining for human CRP was
always more intense than for rat CRP, although it is not
clear whether this represents greater abundance of the hu-
man protein in the tissue sections or just greater sensitivity
of the respective immunostaining procedure. Numerous
 
mononuclear cells in the dense periinfarct infiltrate also
stained strongly for human CRP (Fig. 2) but not for rat CRP
(not shown) or rat C3 (Fig. 2).
 
Cardioprotective Effect of Complement Depletion.
 
Marked
reductions in infarct size and in ischemia/reperfusion injury
have previously been demonstrated in animals in which
complement activation had been blocked by treatment, ei-
ther with cobra venom factor or with recombinant soluble
complement receptor type 1, before or at the time of in-
duction of ischemia (4–8). The therapeutic implications of
this observation are obvious, but for clinical implementa-
tion, it is critical to know whether complement depletion
initiated after the onset of coronary occlusion can still have
a protective effect. We therefore administered cobra venom
factor at various times between 24 h before and 24 h after
coronary artery ligation. There was, as shown before, a
marked, 
 
z
 
60% reduction in infarct size in rats that had re-
 
Table II.
 
Complement Dependence of the Enhancement of Infarct Size by Human CRP
 
Treatment No. treated Day 5 survivors
Infarct size
mean (SD)
Bonferroni 
 
t
 
 test
vs. controls
 
%
 
Buffer only 8 8 14.3 (1.2) –
Human CRP 5 3 19.7 (1.6)
 
P
 
 
 
5
 
 0.0020
Complement
depletion 5 5 6.5 (0.9)
 
P
 
 
 
5
 
 0.0000
Complement
depletion 
 
1
 
human CRP 6 6 6.9 (0.3)
 
P
 
 
 
5
 
 0.0000
Human CRP at 40 mg/kg was injected intraperitoneally 1 h after coronary artery ligation and then at 24-h intervals until all rats were killed 5 d later;
controls received buffer alone. Parallel groups had been decomplemented by intraperitoneal injection of cobra venom factor at 250 U/kg 24 h before
coronary artery ligation.
Figure 2. Immunohistochemical staining of rat myocardial infarcts on day 5. (a) Hematoxylin and eosin stain showing infarcted myocardial cells and ad-
jacent dense mononuclear cell infiltrate. (b) Immunostain with anti–human CRP with uptake localized to the infarcted area and both diffuse and focal pat-
terns of immunoreactivity; many of the adjacent infiltrating macrophages are also immunoreactive. (c) Immunostain with anti–human CRP preabsorbed
with isolated pure human CRP, showing complete absence of any staining and confirming the immunospecificity for human CRP of the pattern observed
in b. (d) Immunostain with anti–rat C3 with uptake confined, in contrast to the anti–human CRP (b), to focal structures, possibly nuclear ghosts, within the
infarct. (e) Immunostain with anti–rat C3 preabsorbed with whole rat serum, showing complete absence of any staining. Absorption of the anti–rat C3 an-
tibody with C3-depleted rat serum did not affect the staining pattern, confirming its immunospecificity for rat C3. Original magnifications, 40. 
1737
 
Griselli et al.
 
ceived treatment 24 h beforehand and that were maximally
complement depleted at the time of operation (Table III).
Although injection of cobra venom factor 6 or 24 h after li-
gation had no effect, the infarcts in animals that received
cobra venom factor either 0.5 or 2 h after ligation were al-
most 50% smaller (Table III). Maximal complement deple-
tion is achieved only from 6 h after intraperitoneal injec-
tion of cobra venom factor, and in this rat model there is
therefore a window of therapeutic opportunity of perhaps
up to 8 h after acute coronary artery occlusion during
which immediate inhibition of complement activation
could potentially reduce infarct size.
 
Discussion
 
CRP has been very stably conserved in evolution (30,
36, 37), and no structural polymorphism or deficiency of
CRP has yet been reported in humans, suggesting that this
protein has important normal functions that contribute to
survival. In experimental models, CRP is protective against
pneumococcal infection (38, 39) and may contribute to in-
nate immunity to other microorganisms to which it binds
(40). By analogy with this role of SAP in relation to chro-
matin that we have recently demonstrated (41), CRP also
probably plays an important role in scavenging autologous
ligands and preventing development of autoimmunity. This
does not mean, however, that CRP may not also contrib-
ute to pathogenesis of disease, especially conditions devel-
oping in postreproductive later life. Natural selection is ‘blind’
to phenomena occurring after reproduction, provided they
do not affect viability of the species as a whole (42).
The results presented here unequivocally demonstrate, in
a robust experimental model, that human CRP markedly
enhances the extent of myocardial damage produced by
ischemic injury. Although the time–concentration profile of
human CRP produced by daily CRP injections was not the
same as the monophasic acute phase response that follows
uncomplicated naturally occurring myocardial infarction in
humans, it was comparable to the persistent, high, and fluc-
tuating CRP pattern typically found in patients with postin-
farct complications (11) and was therefore not ‘unphysio-
logical.’ Endogenous rat CRP, as well as the injected human
CRP, was deposited in the infarct in vivo, but rat CRP
does not activate rat complement (28). In contrast, human
CRP is a potent activator of rat complement (28), and the
enhancement of infarct size caused by administration of
human CRP is completely abrogated by in vivo comple-
ment depletion. Human CRP production is always greatly
increased after acute myocardial infarction, CRP is always
deposited in human myocardial infarcts, and early and late
clinical outcomes are significantly associated with peak
postinfarction plasma levels of CRP. It is therefore very
likely that CRP contributes significantly to the extent of
damage in human acute myocardial infarction, and, based
on our results here, it probably does so via complement ac-
tivation. Although complement activation by CRP is not
efficient in generating the terminal lytic complement com-
plex, it very effectively cleaves C3, the critical step for op-
sonization by C3b and liberation of the C3a anaphylatoxin.
These findings have important therapeutic implications,
suggesting that a drug capable of inhibiting the binding of
human CRP to its target ligands in vivo and thereby pre-
venting it from activating complement should reduce in-
farct size, with corresponding clinical benefit. Furthermore,
increased CRP production is a feature of the nonspecific
acute phase response to a very wide range of traumatic, in-
fectious, inflammatory, and neoplastic tissue-damaging con-
ditions (31). In all of these, including disorders as diverse as
burns, surgical trauma, rheumatoid arthritis, sepsis, and inva-
sive neoplasia, there are nonirremediably damaged cells that,
by analogy with myocardial infarction, are likely to be tar-
geted by the opsonic and proinflammatory actions of CRP
and complement. Specific inhibition of CRP binding in vivo
might thus be expected to be of wide clinical benefit, and
suitable compounds are currently being sought, supported by
our recent description of the high resolution 3-dimensional
structure of the physiological CRP–ligand complex (43).
The cardioprotective effect of total complement deple-
tion at the time of experimental coronary artery occlusion
is well established (4–8). However, in the clinical context
 
Table III.
 
Cardioprotective Effect of Complement Depletion in Myocardial Infarction
 
Cobra venom factor treatment No. of rats
Infarct size on day 5
mean (SD)
Bonferroni 
 
t
 
 test
vs. controls
 
%
 
None, buffer only 4 17.7 (1.9)
24 h before coronary ligation 4 7.0 (1.2)
 
P
 
 
 
5
 
 0.0002
0.5 h after coronary ligation 4 9.7 (1.1)
 
P
 
 
 
5
 
 0.0007
2 h after coronary ligation 4 9.5 (1.6)
 
P
 
 
 
5
 
 0.0011
6 h after coronary ligation 4 16.9 (2.2) NS
24 h after coronary ligation 4 16.9 (1.2) NS
Cobra venom factor at 250 U/kg was injected intraperitoneally at the times shown in relation to coronary artery ligation; controls received buffer
only. All rats were killed after 5 d for estimation of infarct size. One-way analysis of variance, total DF 
 
5
 
 23, F 
 
5
 
 36.45, 
 
P
 
 
 
5
 
 0.0000. 
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of patients presenting with acute myocardial infarction,
complement depletion could only be initiated after the on-
set of symptoms. We show here that injection of cobra
venom factor up to 2 h after ligation of the coronary artery
significantly reduces infarct size, despite the fact that maxi-
mal depletion of plasma C3 is only achieved 6 h after cobra
factor administration. This encouragingly suggests that, af-
ter acute ischemia, the major pathogenic action of comple-
ment occurs after some hours, and there is therefore a win-
dow of therapeutic opportunity during which inhibition of
complement activation could still reduce infarct size, with
corresponding reduction in morbidity and mortality. Al-
though no anticomplement drugs are yet in clinical use,
our results support their development and testing.
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